Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA – Get Free Report) have been given an average rating of “Moderate Buy” by the seven research firms that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $22.57.
A number of analysts have issued reports on the company. William Blair reaffirmed an “outperform” rating on shares of Neumora Therapeutics in a research note on Friday, April 12th. JPMorgan Chase & Co. boosted their price target on shares of Neumora Therapeutics from $20.00 to $22.00 and gave the stock an “overweight” rating in a research report on Monday, March 18th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $31.00 price objective on shares of Neumora Therapeutics in a research report on Thursday, March 28th.
Read Our Latest Research Report on Neumora Therapeutics
Neumora Therapeutics Stock Up 1.0 %
Neumora Therapeutics (NASDAQ:NMRA – Get Free Report) last released its quarterly earnings data on Thursday, March 7th. The company reported ($0.71) EPS for the quarter, beating the consensus estimate of ($0.76) by $0.05. Sell-side analysts predict that Neumora Therapeutics will post -1.48 earnings per share for the current year.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently bought and sold shares of NMRA. Addis & Hill Inc bought a new stake in shares of Neumora Therapeutics in the 1st quarter worth about $4,187,000. Windmill Hill Asset Management Ltd purchased a new stake in Neumora Therapeutics in the 1st quarter worth about $359,000. Avidity Partners Management LP lifted its stake in Neumora Therapeutics by 10.6% in the fourth quarter. Avidity Partners Management LP now owns 1,990,632 shares of the company’s stock worth $33,940,000 after purchasing an additional 190,632 shares during the last quarter. Tower Research Capital LLC TRC purchased a new position in shares of Neumora Therapeutics during the fourth quarter valued at approximately $44,000. Finally, Amalgamated Bank bought a new position in shares of Neumora Therapeutics during the fourth quarter valued at approximately $29,000. 47.65% of the stock is owned by hedge funds and other institutional investors.
About Neumora Therapeutics
Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.
Featured Stories
- Five stocks we like better than Neumora Therapeutics
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- 3 Stocks Leading the U.S. Agriculture Comeback
- What Are Dividend Champions? How to Invest in the Champions
- How to Use Put Debit Spreads to Profit From Falling Stocks
- What is Insider Trading? What You Can Learn from Insider Trading
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for Neumora Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neumora Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.